Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : China symbols : AZN save search
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
Published: 2023-01-18 (Crawled : 15:00) - globenewswire.com
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: 1.32%
H: 4.49%
C: 1.01%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.36%
H: 0.33%
C: -1.13%
orpathys drug agreement china
Global Drug Discovery Technologies Market Report 2022-2026: China and India - Hot Spots for R&D Investment
Published: 2022-03-22 (Crawled : 16:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 2.88%
H: 2.09%
C: 2.09%
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: 1.4%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: 0.0%
A | $132.73 0.22% 0.0% 1.3M
|
Health Technology
|
| O: -0.09%
H: 1.59%
C: 0.93%
ILMN | $117.43 0.63% 0.63% 1.4M
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.51%
H: 0.0%
C: 0.0%
drug report china india
China Oncology Drugs Market to Cross $35.2 Billion by 2027 - Insights Into the Leading Therapies, Indications, Drugs, and Companies
Published: 2022-02-18 (Crawled : 15:30) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -0.64%
H: 0.0%
C: -2.99%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.73%
H: 0.23%
C: -0.98%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.19%
H: 0.72%
C: -0.46%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.02%
H: 0.43%
C: -0.84%
drug china therapy
HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy
Published: 2021-11-24 (Crawled : 01:00) - globenewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -0.02%
H: 1.33%
C: 1.33%
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: -4.39%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
orpathys lung cancer china therapy cancer trial
HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
Published: 2021-09-08 (Crawled : 11:00) - globenewswire.com
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: -2.29%
H: 1.34%
C: 1.29%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.85%
H: 0.17%
C: -0.42%
lung cancer china therapy cancer trial
HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a US$25 million Milestone Payment from AstraZeneca
Published: 2021-07-13 (Crawled : 07:00) - globenewswire.com
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: -0.45%
H: 2.92%
C: 2.12%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.68%
H: 0.94%
C: 0.87%
china milestone commercialization
HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations
Published: 2021-06-22 (Crawled : 18:00) - globenewswire.com
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: 3.66%
H: 1.31%
C: -4.82%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.26%
H: 0.28%
C: -0.46%
lung cancer china cancer
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.